PR Newswire All News ReleasesCodex · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 04:04:00·⟳ 抓取 04:05:06 +1m06s·⚡ 决策 08-28 13:31:03 +9h25m·60.4 天前
Pomerantz再次提醒Regeneron投资者证券集体诉讼及9月14日首席原告期限
本条不是新的临床失败、监管处罚或法院实质进展，而是律师广告式诉讼提醒；直接标的Regeneron已有4月和5月两轮基本面负面披露及价格反应，当前信息不足以支持新开空或做多。
📄 原文PR Newswire All News Releases↗ 原文
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rege…
不做 Regeneron Pharmaceuticals（REGN.US）
不做Regeneron Pharmaceuticals（REGN.US）：本条只是Pomerantz对既有证券集体诉讼和首席原告期限的提醒，核心临床失败和股价下跌已在4月/5月发生；没有新增法律量级或监管实质进展，做空催化强度不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Pomerantz新闻稿把Regeneron既有Fianlimab-Libtayo三期PFS未达标事件包装为证券诉讼提醒；Regeneron公司官网已在2026-05-15披露该三期试验未达主要终点，4月29日业绩电话会和5月15日公告后的跌幅也已在诉讼材料中列明。本次新增事实主要是首席原告期限提醒，不改变药物成功概率、收入基线、赔偿量级或法院阶段，因此不做。
消息传播链
- Regeneron一手披露Fianlimab联合Libtayo三期试验未达到PFS主要终点统计显著。市场反应:Pomerantz材料称REGN随后单日下跌约9.8%。
- Pomerantz发布投资者提醒，提示既有证券集体诉讼和2026-09-14首席原告期限。市场反应:新闻发布在美股收盘后，公开报价页显示8月27日收盘REGN约807.71美元，盘后4:04无变化。
关键理由
- Regeneron官网于2026-05-15已披露Fianlimab三期PFS主要终点未达统计显著，本条律师提醒不是新的临床数据。
- 诉讼新闻稿列明4月29日和5月15日后REGN分别下跌约6.2%和9.8%，说明核心负面事实已被市场定价过。
- 截至公开材料，本条未给出赔偿金额、法院受理实质进展或新增监管处罚，无法量化对约806亿美元市值公司的新增损害。
主要风险
- 若后续法院文件披露高额索赔、正式认定误导披露或监管介入，REGN.US可能再被下修法律风险溢价。
- Fianlimab项目本身仍有研发管线不确定性，但该风险来自5月临床读出而非本条提醒。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-27 · 影响 weakens
检索到的材料主要是律师事务所征集提醒和旧临床失败事实，未见新增法院裁定、和解金额或监管处罚。
检索:Regeneron Fianlimab Libtayo class action lawsuit August 2026 new court ruling settlement regulatory action 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-05-15 · 影响 weakens
公司一手披露已经发生在5月15日，当前新闻未改变临床项目事实状态。
检索:Regeneron May 15 2026 Fianlimab phase 3 PFS not statistically significant company release 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加无新增事实，使订单从潜在SHORT降为AVOID。
方向:未使用可量化先例；律师事务所对既有集体诉讼的重复提醒通常不等同于新的可交易法律风险事件。
涨幅量级:无高相似、锚点干净且可用event_study测算的样本，不能据此给出做空幅度。
形态:本条的核心可迁移模式是旧负面事实后的诉讼提醒，通常更像信息再扩散而非基本面重定价。
原文全文
展开原文 · 2,485 字
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until September 14, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Regeneron securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On April 29, 2026, during during Regeneron's first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival."
On this news, Regeneron's stock price fell $45.41 per share, or 6.21%, to close at $686.36 per share on April 29, 2026.
Then, on May 15, 2026, Regeneron issued a press release disclosing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)."
On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The class action concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until September 14, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Regeneron securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On April 29, 2026, during during Regeneron's first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival."
On this news, Regeneron's stock price fell $45.41 per share, or 6.21%, to close at $686.36 per share on April 29, 2026.
Then, on May 15, 2026, Regeneron issued a press release disclosing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)."
On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。